![](https://investorshub.advfn.com/uicon/85886.png?cb=1464343178)
Wednesday, February 02, 2022 11:02:41 AM
ABUS has been the topic of a number of other reports. JMP Securities lifted their price objective on shares of Arbutus Biopharma from $7.00 to $9.00 and gave the stock a "market outperform" rating in a report on Monday, November 8th. Chardan Capital upped their price target on Arbutus Biopharma from $5.00 to $5.50 and gave the company a "buy" rating in a research report on Thursday, December 2nd. Zacks Investment Research upgraded shares of Arbutus Biopharma from a "hold" rating to a "buy" rating and set a $4.00 price objective on the stock in a research report on Monday, January 10th. Finally, HC Wainwright cut their target price on Arbutus Biopharma from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Monday, November 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Arbutus Biopharma has a consensus rating of "Buy" and a consensus target price of $6.42.
NASDAQ:ABUS opened at $2.92 on Wednesday. Arbutus Biopharma has a 52 week low of $2.38 and a 52 week high of $6.50. The firm has a market cap of $394.99 million, a price-to-earnings ratio of -3.21 and a beta of 2.74. The firm's 50-day simple moving average is $3.58 and its 200 day simple moving average is $3.5
Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings results on Thursday, November 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, hitting analysts' consensus estimates of ($0.24). The business had revenue of $3.34 million for the quarter, compared to the consensus estimate of $2.36 million. During the same period in the prior year, the business posted ($0.27) earnings per share. As a group, analysts anticipate that Arbutus Biopharma will post -0.86 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in Arbutus Biopharma by 1.7% during the 3rd quarter. BlackRock Inc. now owns 5,935,203 shares of the biopharmaceutical company's stock valued at $25,463,000 after acquiring an additional 99,630 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Arbutus Biopharma by 31.9% in the 2nd quarter. Vanguard Group Inc. now owns 3,736,233 shares of the biopharmaceutical company's stock worth $11,321,000 after buying an additional 904,006 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Arbutus Biopharma by 19.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,540,431 shares of the biopharmaceutical company's stock worth $6,608,000 after buying an additional 253,773 shares during the period. State Street Corp lifted its holdings in shares of Arbutus Biopharma by 1,942.2% in the 2nd quarter. State Street Corp now owns 1,156,094 shares of the biopharmaceutical company's stock worth $3,503,000 after buying an additional 1,099,484 shares during the period. Finally, Two Sigma Investments LP lifted its holdings in shares of Arbutus Biopharma by 187.7% in the 3rd quarter. Two Sigma Investments LP now owns 730,298 shares of the biopharmaceutical company's stock worth $3,133,000 after buying an additional 476,475 shares during the period. Hedge funds and other institutional investors own 54.51% of the company's stock.
https://www.marketbeat.com/instant-alerts/nasdaq-abus-a-buy-or-sell-right-now-2022-02/
You can lead a horse to water. But you can't make him get down on one knee and do an Al Jolson impression!
Recent ABUS News
- Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 07/18/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 03:16:15 PM
- Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels • GlobeNewswire Inc. • 06/06/2024 03:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 10:00:21 AM
- Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure • GlobeNewswire Inc. • 06/05/2024 06:30:00 AM
- Arbutus to Participate in Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:25:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:10:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:07:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 10:00:18 AM
- Arbutus to Present Imdusiran Data at EASL Congress 2024 • GlobeNewswire Inc. • 05/22/2024 06:00:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 01:03:23 PM
- Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value • Business Wire • 05/17/2024 01:00:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/09/2024 12:00:20 PM
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 11:30:00 AM
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 • GlobeNewswire Inc. • 05/02/2024 11:25:00 AM
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/18/2024 11:30:00 AM
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna • GlobeNewswire Inc. • 04/04/2024 12:30:49 PM
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 03/08/2024 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 09:48:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:31:15 PM
- Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/29/2024 12:30:00 PM
- Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 02/15/2024 12:30:00 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM